Healthcare Pricing Debate
Chamath and David discuss the pros and cons of regulating healthcare pricing, with Chamath highlighting the potential inflation and lack of guaranteed cure, while David emphasizes the value of market opportunities and the potential for improving treatments for debilitating diseases like Duchenne muscular dystrophy. Jason adds insights on the incentives for drug companies and the market impact of recent FDA approvals.In this clip
From this podcast
All-In Podcast
E35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, Bitcoin & more
Related Questions
Why are pharmaceuticals so expensive, as discussed in the episode 1005: David Fajgenbaum | Leveraging AI to Cure Rare Diseases and the clip Drug Pricing Dilemma?
Why are prescription drugs so expensive, as discussed in the episode 1005: David Fajgenbaum | Leveraging AI to Cure Rare Diseases and the clip Drug Pricing Dilemma?
Why are prescription drugs so expensive, as discussed in the episode 1005: David Fajgenbaum | Leveraging AI to Cure Rare Diseases and the clip Drug Pricing Dilemma?